SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates HZN, ANGN, CNCE

NEW YORK, Jan. 26, 2023

Horizon Global Corporation (NYSE: HZN)'s sale to First Brands Group, LLC for $1.75 per share. If you are a Horizon Global shareholder, click here to learn more about your legal rights and options.   

Angion Biomedica Corp. (NASDAQ: ANGN)'s merger with Elicio Therapeutics. Under the terms of the merger agreement, Elicio shareholders will receive newly issued shares of Angion common stock and current Angion shareholders are expected to own approximately 34.5% of the newly combined company. If you are an Angion shareholder, click here to learn more about your rights and options.

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE)'s sale to Sun Pharmaceutical Industries Limited. Per the terms of the agreement, Sun Pharma would acquire Concert for an upfront payment of $8.00 per share in cash, plus a non-tradeable contingent value right entitling Concert shareholders to receive up to an additional $3.50 per share in cash, payable upon deuruxolitinib achieving certain net sales milestones within specified periods. If you are a Concert shareholder, click here to learn more about your rights and options.

Halper Sadeh LLC may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits on behalf of shareholders.

Shareholders are encouraged to contact the firm free of charge to discuss their legal rights and options. Please call Daniel Sadeh or Zachary Halper at (212) 763-0060 or email sadeh@halpersadeh.com or zhalper@halpersadeh.com.